Medical Terms in the Field of Oncology

-  Croal, B. (2017). The communication of critical and unexpected pathology results. The Royal College of Pathologists. Available at: https://www.rcpath.org/uploads/assets/bb86b370-1545-4c5a-b5826a2c431934f5/The-communication-of-critical-and-unexpected-pathology-results.pdf. Accessed August 2019.

-  National Cancer Institute. (2019). Tumor markers in common use. Available at: https://www.cancer.gov/about-cancer/diagnosis-staging/diagnosis/tumor-markers-list. Accessed August 2019.

-  American Association for Clinical Chemistry. (2019). Lab tests online. Available at: https://labtestsonline.org/articles/patient-tools. Accessed August 2019.

-  NeoGenomics. (2019). BTK Inhibitor acquired resistance panel. Available at: https://neogenomics.com/test-menu/btk-inhibitor-acquired-resistance-panel. Accessed August 2019.

-  National Cancer Institute. (2019). BRCA mutations: Cancer risk and genetic testing. Available at: https://www.cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheet#q1. Accessed August 2019.

-  Naeim, F., Rao, P. N., Son, S. X., & Phan, R. T. (2018). Atlas of hematology: Morphology, immunophenotype, cytogenetics, and molecular approaches (2nd ed.). Elsevier, Inc. https://doi.org/10.1016/C2015-0-05997-4.

-  Pernick, N. (2013). CD25. Pathology Outlines. Available at: https://www.pathologyoutlines.com/topic/cdmarkerscd25.html. Accessed August 2019.

-  Jain, N., & O’Brien, S. (2012). Chronic lymphocytic leukemia with deletion 17p: Emerging treatment options. Available at: https://www.cancernetwork.com/hematologic-malignancies/chronic-lymphocytic-leukemia-deletion-17p-emerging-treatment-options. Accessed August 2019.

-  Helsten, T., et al. (2016). The FGFR landscape in cancer: Analysis of 4,853 tumors by next-generation sequencing. Clinical Cancer Research, 22(1), 259-267. Available at: http://clincancerres.aacrjournals.org/content/22/1/259.full-text.pdf. Accessed August 2019.

-  Genetics Home Reference. (2019). HRAS gene. Available at: https://ghr.nlm.nih.gov/gene/HRAS#. Accessed August 2019.

-  Roychowhurdy, M. (2019). Stains: Ki67 / MIB1. Pathology Outlines. Available at: [link missing].

-  Association of Oncology Nurse Navigators+. (2018). Clinical relevance and rationale of using MSI-H/dMMR biomarkers in immunotherapy of colorectal cancer and other solid tumors. Available at: https://aonnonline.org/component/mams/?view=article&secid=180:faculty-perspectives-clinical-relevance-and-rationale-of-using-msi-h-dmmr-biomarkers-in-immunotherapy-of-colorectal-cancer-and-other-solid-tumors-and-part-3-of-a-4-part-series&artid=2068:clinical-relevance-and-rationale-of-using-msi-h-dmmr-biomarkers-in-immunotherapy-of-colorectal-cancer-and-other-solid-tumors. Accessed August 2019.